Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 120
- Registration Number
- NCT06976372
- Locations
- 🇺🇸
CenExel, Anaheim, California, United States
🇺🇸CenExel Collaborative Neuroscience Research, LLC Los Alamitos, Los Alamitos, California, United States
🇺🇸Fortrea Clinical Research Unit - Dallas, Dallas, Texas, United States
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AMG 378Drug: Placebo
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 92
- Registration Number
- NCT06910709
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT06898957
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3501
- Registration Number
- NCT06858839
- Locations
- 🇺🇸
Indago Research and Health Center, Hialeah, Florida, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Pinnacle Research Group LLC, Anniston, Alabama, United States
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 999
- Registration Number
- NCT06858878
- Locations
- 🇺🇸
Alliance for Multispecialty Research Mobile, Mobile, Alabama, United States
🇺🇸Gilbert Center for Family Medicine, Gilbert, Arizona, United States
🇺🇸Desert Clinical Research, Mesa, Arizona, United States
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
- Conditions
- Obesity
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT06761703
- Locations
- 🇺🇸
YourBio Health/CRT, Medford, Massachusetts, United States
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 844
- Registration Number
- NCT06747949
- Locations
- 🇺🇸
Bradenton Research Center Inc, Bradenton, Florida, United States
🇺🇸Arthritis, Rheumatic & Bone Disease Associates - P, Voorhees, New Jersey, United States
🇺🇸Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St, Gilbert, Arizona, United States
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT06745323
- Locations
- 🇹🇷
Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi, Ankara, Turkey
🇺🇸New York Oncology Hematology PC, Albany, New York, United States
🇺🇸FirstHealth Cancer Center, Pinehurst, North Carolina, United States
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 444
- Registration Number
- NCT06700343
- Locations
- 🇺🇸
Profound Research - Neurology Center of Southern California, Carlsbad, California, United States
🇺🇸Mountain Neurological Research Center, Basalt, Colorado, United States
🇺🇸Advanced Neurosciences Research, Llc, Fort Collins, Colorado, United States
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- 🇨🇦
Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada
🇩🇰Vejle Sygehus, Vejle, Denmark
🇺🇸City of Hope National Medical Center, Duarte, California, United States